^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
Published date:
01/17/2023
Excerpt:
Compared to mGC with other genetic alterations (n=25), mGC with TMB >20/Mb or MSI-high mGC (n=23) tended to have a higher ORR (56.5% vs 48%), and a prolonged PFS (median 7.2 vs 4.5 months; 44.0 vs 20.8% at 1 year)….The combination chemotherapy of durvalumab, tremelimumab, and paclitaxel showed encouraging efficacy, especially in mGC with TMB >20/Mb or MSI-high mGC, as a second-line chemotherapy with manageable toxicities in biomarker-selected mGC.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2023.41.3_suppl.401
Trial ID:
